VISTA, Calif.--(BUSINESS WIRE)--Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the manual read of digital HER2 slides from a computer monitor using its patented ScanScope® digital slide scanning system. The FDA-cleared system is intended for use as an accessory to the Dako HercepTest™ to aid pathologists in the detection and semi-quantitative measurement of HER2 protein expression to assess breast cancer patients for whom HERCEPTIN® treatment is being considered.
